Sona Nanotech Inc. SNANF
Set alert
At close · Oct 30
- YTD
- -42.69%
- 1 year
- -57.45%
- Open
- 0.2001
- Prev close
- 0.20
- Mkt cap
- 24.56M
- Vol
- 23.50K
- Avg vol
- 4.86K
- EPS
- -0.02
- P/E
- 0.00
More statistics
- Low
- 0.20
- High
- 0.2001
News
1 month ago globenewswire.com
Sona Nanotech to Present at the OTC Markets' Life Sciences Virtual Investor Forum On September 17th
HALIFAX, Nova Scotia, Sept. 11, 2026 (GLOBE NEWSWIRE) -- Sona Nanotech Inc. (CSE: SONA), (OTCQB: SNANF), an oncology company developing a therapy to increase the limited efficacy of immunotherapy…
6 months ago proactiveinvestors.com
Dow rockets higher as Strait of Hormuz stays open, talks eyed
4:20pm: Easing tensions Markets finished the session on a strong note, with major US indexes extending their winning streak as geopolitical tensions showed...
6 months ago proactiveinvestors.com
Iran's blockade of the Strait of Hormuz has wiped out a third of global helium supply, and the scramble for secure alternatives has begun
The gas keeping the world's MRI scanners running and AI chips cool is suddenly in critically short supply. Six ASX-listed companies could find themselves in...
6 months ago proactiveinvestors.com
Dow powers higher as oil slump, easing tensions lift stocks
12:55pm: Sliding oil propels stocks "Crude futures prices fell sharply - dropping over 10% to below $86 per barrel and reaching near five-week lows - after...
6 months ago proactiveinvestors.com
Hims & Hers shares jump as FDA begins review of restricted peptide compounds
Shares of Hims & Hers Health (NYSE:HIMS) rose more than 8% to about $26 after the US Food and Drug Administration (FDA) moved to begin a formal review...
6 months ago proactiveinvestors.com
Sona Nanotech appoints two oncologists to scientific advisory board
Sona Nanotech Inc (CSE:SONA, OTCQB:SNANF) has announced the appointment of two oncologists, Michael Smylie and Jonathan Trites, to its scientific advisory board to support its ongoing clinical and…
-
6 months ago proactiveinvestors.com
Sona Nanotech appoints two oncologists to scientific advisory board
Sona Nanotech Inc (CSE:SONA, OTCQB:SNANF) has announced the appointment of two oncologists, Michael Smylie and Jonathan Trites, to its scientific advisory...
6 months ago proactiveinvestors.com
Sona Nanotech reports immune activation in melanoma trial of heat-based therapy
Sona Nanotech Inc (CSE:SONA, OTCQB:SNANF) said tissue analysis from its first human trial of its heat-based cancer therapy showed immune system activation in late-stage melanoma patients, raising…
6 months ago proactiveinvestors.com
Alien Metals shares jump 16% as joint ventures advance drilling at two Western Australia precious metal projects
Shares in Alien Metals (AIM: UFO) rose 16% to 0.12p after the company reported progress at two separate joint venture projects in the Pilbara region of...
6 months ago proactiveinvestors.com
FTSE 100 Live: Aero and defence stocks lead decline as Trump's Iran deadline looms
FTSE down 82 points at 10,354 Oil and gas prices remain elevated Pres Trump set a 1am GMT deadline for Iran deal 4.03pm: Defence and aerospace stocks...
6 months ago proactiveinvestors.com
Sona Nanotech preclinical study shows tumor regression in colorectal cancer model
Sona Nanotech Inc (CSE:SONA, OTCQB:SNANF) has announced the publication of a preclinical study examining the efficacy of its Targeted Hyperthermia Therapy (THT) in combination with immunotherapy for…
6 months ago proactiveinvestors.com
Sona Nanotech preclinical study shows tumor regression in colorectal cancer model
Sona Nanotech Inc (CSE:SONA, OTCQB:SNANF) has announced the publication of a preclinical study examining the efficacy of its Targeted Hyperthermia Therapy...
8 months ago proactiveinvestors.com
Why precision oncology may be poised for a reset: a conversation with Sona Nanotech
Cancer has quietly become the pharmaceutical industry's most lucrative disease area. In 2024 alone, global cancer drug sales exceeded $200 billion, making oncology the single largest revenue category…
1 year ago proactiveinvestors.com
Sona Nanotech CEO on breakthrough cancer therapy results - ICYMI
Sona Nanotech Inc (CSE:SONA, OTCQB:SNANF) has reported promising first-in-human results for its targeted hyperthermia therapy (THT), showing tumor elimination in most treated patients with advanced…
1 year ago proactiveinvestors.com
Sona Nanotech poised for clinical breakthrough after melanoma study
Sona Nanotech Inc (CSE:SONA, OTCQB:SNANF) is stepping into clinical-stage biotech after reporting promising results from its first-in-human trial of Targeted Hyperthermia Therapy (THT) for advanced…
1 year ago proactiveinvestors.com
Sona Nanotech reveals positive response rate in first-in-human THT cancer therapy study
Sona Nanotech Inc (CSE:SONA, OTCQB:SNANF) Inc announced that it has completed its first-in-human clinical study treating patients with histologically confirmed, immunotherapy-resistant cutaneous…
1 year ago newsfilecorp.com
Sona Nanotech Reports 80% Response Rate in First-In-Human THT Cancer Therapy Study
-- Six out of ten patients experienced complete responses in treated tumors with an additional two patients demonstrating partial responses - confirmed in a representative tumor biopsy - all within…
1 year ago newsfilecorp.com
Sona Nanotech To Host Investor Webinar To Discuss Clinical Study
Halifax, Nova Scotia--(Newsfile Corp. - October 17, 2025) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona"), announces that it will host a webinar on Monday, October 20th at…
1 year ago proactiveinvestors.com
Sona Nanotech advances first-in-human cancer therapy trial
Sona Nanotech Inc (CSE:SONA, OTCQB:SNANF) announced that it has completed treatment and follow-up assessments for the first cohort of patients in its early feasibility study of Targeted Hyperthermia…
1 year ago newsfilecorp.com
Sona Provides Update on First-In-Human Clinical Trial
Halifax, Nova Scotia--(Newsfile Corp. - August 25, 2025) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona"), an oncology-focused life sciences company developing innovative…